Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 934,846
  • Shares Outstanding, K 43,021
  • Annual Sales, $ 700,970 K
  • Annual Income, $ -99,560 K
  • EBIT $ 99 M
  • EBITDA $ 181 M
  • 60-Month Beta 0.24
  • Price/Sales 1.39
  • Price/Cash Flow 4.92
  • Price/Book 1.31

Options Overview Details

View History
  • Implied Volatility 56.84% (-36.02%)
  • Historical Volatility 56.88%
  • IV Percentile 26%
  • IV Rank 22.05%
  • IV High 119.80% on 10/30/25
  • IV Low 39.03% on 08/20/25
  • Expected Move (DTE 8) 1.49 (6.85%)
  • Put/Call Vol Ratio 4.00
  • Today's Volume 5
  • Volume Avg (30-Day) 45
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 1,278
  • Open Int (30-Day) 1,329
  • Expected Range 20.23 to 23.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.60
  • Number of Estimates 3
  • High Estimate 0.67
  • Low Estimate 0.56
  • Prior Year 0.71
  • Growth Rate Est. (year over year) -15.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.80 +14.63%
on 01/20/26
22.95 -6.10%
on 01/13/26
-1.38 (-6.02%)
since 01/12/26
3-Month
18.80 +14.63%
on 01/20/26
27.16 -20.66%
on 12/16/25
-2.31 (-9.68%)
since 11/12/25
52-Week
18.80 +14.63%
on 01/20/26
27.64 -22.03%
on 09/03/25
-5.58 (-20.57%)
since 02/12/25

Most Recent Stories

More News
Pacira Highlights New NOPAIN Act Survey Data Conducted by Voices for Non-Opioid Choices

BRISBANE, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies, today highlighted...

PCRX : 21.55 (-0.83%)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients,...

PCRX : 21.55 (-0.83%)
Pacira BioSciences Appoints Samit Hirawat, M.D., to Board of Directors

-- Veteran Executive Brings More Than 25 Years of Clinical Development and Industry Expertise -- BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry...

PCRX : 21.55 (-0.83%)
Pacira Announces Agreement with LG Chem to Make EXPAREL® Available in Select Asian-Pacific Markets

-- LG Chem becomes exclusive distributor of EXPAREL --  – Partnership expands patient access to opioid-sparing pain control and advances 5x30 strategy– BRISBANE, Calif., Jan. 13, 2026 ...

PCRX : 21.55 (-0.83%)
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues

-- Record-high EXPAREL sales driven by volume growth of 7 percent, marking strongest fourth quarter performance in three years-- BRISBANE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences,...

PCRX : 21.55 (-0.83%)
Pacira BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conferences

BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives...

PCRX : 21.55 (-0.83%)
DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.

Restates Position that Pacira's Board Should Conduct Formal Sales Process of the Business

PCRX : 21.55 (-0.83%)
Pacira Biosciences Joins PROBE Consortium to Transform Osteoarthritis Research and Care

--Public-private partnership aims to improve osteoarthritis research, diagnosis and treatment-- --PROBE will leverage data from over 70 million individuals across multiple OA cohorts and real-world registries--...

PCRX : 21.55 (-0.83%)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients,...

PCRX : 21.55 (-0.83%)
Pacira BioSciences Announces Results From 12-Month Pilot Study Demonstrating Favorable Safety and Significant Improvements in Pain With iovera° Compared to Radiofrequency Ablation in Chronic Low Back Pain

-- New data published in Pain Physician shows significant improvement in functional outcomes with iovera° -- -- Fewer iovera° patients required additional spine injections after 180 days -- --  No...

PCRX : 21.55 (-0.83%)

Business Summary

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug...

See More

Key Turning Points

3rd Resistance Point 23.35
2nd Resistance Point 22.68
1st Resistance Point 22.21
Last Price 21.55
1st Support Level 21.07
2nd Support Level 20.40
3rd Support Level 19.93

See More

52-Week High 27.64
Fibonacci 61.8% 24.26
Fibonacci 50% 23.22
Fibonacci 38.2% 22.18
Last Price 21.55
52-Week Low 18.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar